Ads
related to: novartis ag adr stock
Search results
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
Zacks via Yahoo Finance· 10 months agoSwiss pharma giant Novartis AG NVS reported strong second-quarter 2023 results and shares are...
Novartis' (NVS) Shareholders Approve Sandoz Separation
Zacks via Yahoo Finance· 8 months agoNovartis AG NVS announced that its shareholders agreed to the proposed 100% spin-off of its generic...
Novartis (NVS) Plans to Spin Off Generics Business Sandoz
Zacks via Yahoo Finance· 2 years agoNovartis NVS has announced plans to spin off Sandoz, its generics and biosimilars division, into a...
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
Zacks via Yahoo Finance· 2 years agoNovartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight...
Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK
Zacks via Yahoo Finance· 4 months agoThe fourth-quarter 2023 reporting cycle of the Medical sector is about to pick up pace this week....
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoIncyte Corporation INCY is scheduled to release its second-quarter 2022 results on Aug 2, before the...
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
Zacks via Yahoo Finance· 1 year agoBayer AG BAYRY released first-quarter 2023 core earnings of 79 cents per American Depositary Receipt...
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
Zacks via Yahoo Finance· 2 years agoThis week, Novartis NVS and Merck MRK announced their third-quarter earnings. The FDA approved J&J’s...
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
Zacks via Yahoo Finance· 2 years agoSanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung...
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
Zacks via Yahoo Finance· 2 years agoShares of Gilead Sciences, Inc. GILD has gained 2.6% in the past three months against the industry’s...
